Palatin has a research program in DR, and more specifically, in diabetic macular edema (DME), a complication of DR that ...

For adults with diabetes, semaglutide treatment is not associated with increased risk of eye disorders or diabetic retinopathy, according to a review published online Aug. 14 in JAMA Ophthalmology.

The agreement with Palatin follows a $1bn deal with Re-Vana earlier this year as Boehringer targets the ophthalmology market.

Ozempic may have serious side effects, including thyroid cancer and problems with the pancreas, gallbladder, kidneys, and ...

Comprehensive eye exams are vital for detecting early signs of systemic diseases like diabetes, hypertension, and high ...

Researchers urged caution, recommending that diabetic patients on GLP-1 therapies undergo regular eye screening….

The NEW DAY study evaluating Iluvien for diabetic macular edema did not meet its primary endpoint, but showed favorable ...

The two aim to develop a potential first-in-class melanocortin receptor-targeted treatment for patients with retinal diseases ...

North America leads market expansion as companies advance next-generation ophthalmic therapies to address rising prevalence ...

THE Georgetown Public Hospital Corporation (GPHC) has been promoting vision care through early screenings and tests at its eye clinic and the Vision Centre.

Novo Nordisk, the manufacturer of Ozempic, is facing a lawsuit over alleged vision problems caused by the drug ...

Ranibizumab's indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration, and ...